Marie-France
Tschudin
  • President of Novartis Pharmaceuticals (Switzerland)
  • Born on September 24, 1971
  • Swiss nationality

Directorship and number of AXA shares

Appointed on June 30, 2020 - Term expires at the 2024 Shareholders’ Meeting
First appointment on June 30, 2020
Number of AXA shares held on December 31, 2019: none

On June 30, 2020

Expertise and experience

Mrs. Marie-France Tschudin graduated with a Master of Business Administration from IMD business school in Switzerland, and a Bachelor of Science from Georgetown University in the United States. Before joining Novartis, Mrs. Marie-France Tschudin spent 10 years at Celgene International in a variety of leadership positions, including country manager of Switzerland from 2008 to 2009, general manager of Austria, Switzerland, the Czech Republic, Poland, Slovenia and Slovakia from 2009 to 2011, regional vice president of northern Europe from 2012 to 2014 and corporate vice president of hematology and oncology for Europe, the Middle East and Africa from 2014 to 2016. She joined Novartis in 2017 as Europe Region Head of Novartis Pharmaceuticals. From March to June 2019, she was President of Advanced Accelerator Applications, a Novartis company. Since June 7, 2019, Mrs. Marie-France Tschudin has been President of Novartis Pharmaceuticals and a member of the Executive Committee of Novartis (Switzerland).

Directorship held within the AXA Group

  • Director: AXA

Directorships held outisde the AXA Group

  • President: Novartis Pharmaceuticals (Switzerland)

Directorships held during the last five years

  • None